Open an account

Schrodinger

SDGR · NASDAQ

$23.40+$0.28 (+1.21%)TodayMarket closed ·
Prev close $23.12

About SDGR

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 850 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Employees
850
Headquarters
New York City, New York
Listed
Feb 6, 2020
Sector
Health Care
Industry
Health Care Technology
Website
schrodinger.com

SDGR key statistics

Market cap
1.75B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.84M
Volume
1.38M
Open price
$22.77
High today
$23.70
Low today
$21.73
52 Week high
$33.78
52 Week low
$10.95

Schrodinger (SDGR) at a glance

As of Oct 20, 2026, Schrodinger (SDGR) shares are priced at $23.40, giving the company a market cap of 1.75B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $21.73 and $23.70. The current price is 7.7% above the day's low and 1.3% below its high.

Volume so far is 1.38M shares, below the average of 2.84M shares a day.

Over the past year Schrodinger has ranged from $10.95 to $33.78, and now sits 55% of the way up that range.

Schrodinger met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.08 per share against an estimate of -$0.4916.

The average analyst price target is $21.86, 6.6% below the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

63%of 8 analyst ratings say Buy
  • Buy62.5%
  • Hold37.5%
  • Sell0.0%
Price target · 9 analystsAvg $21.86
Low
$17.17
Now
$23.40
High
$31.50

SDGR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 106.5% on average.

  1. Q3 FY24: reported -$0.52 per share against an estimate of -$0.6079
  2. Q4 FY24: reported -$0.55 per share against an estimate of -$0.4277
  3. Q1 FY25: reported -$0.82 per share against an estimate of -$0.7594
  4. Q2 FY25: reported -$0.59 per share against an estimate of -$0.7831
  5. Q3 FY25: reported -$0.45 per share against an estimate of -$0.7206
  6. Q4 FY25: reported $0.45 per share against an estimate of -$0.1877
  7. Q1 FY26: reported -$0.81 per share against an estimate of -$0.647
  8. Q2 FY26: reported $0.08 per share against an estimate of -$0.4916

SDGR news

  • Press releaseBusiness Wire

    Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

  • Chris Katje

    Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You

  • Press releaseBusiness Wire

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033

  • Press releaseBusiness Wire

    Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

  • Press releasePRNewswire

    AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030

  • Press releaseBusiness Wire

    Schrödinger to Present at Morgan Stanley Global Healthcare Conference

  • Press releaseBusiness Wire

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Similar companies

Companies in the same industry as Schrodinger

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.